Xeris Biopharma Holdings, Inc. reports results for the quarter ended June 30 - Earnings Summary

Xeris Biopharma Holdings

06/08/2026 14:31

Xeris Biopharma Holdings, Inc. XERS.OQ reported a quarterly adjusted loss of 18 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -1 cents.  The mean expectation of seven analysts for the quarter was for breakeven results per share. Wall Street expected results to range from -2 cents to 2 cents per share.
Revenue rose 28.7% to $92.10 million from a year ago; analysts expected $90.23 million. 
Xeris Biopharma Holdings, Inc.'s reported EPS for the quarter was a loss of 18 cents​.
The company reported a quarterly loss of $31.1 million.
Xeris Biopharma Holdings, Inc. shares had risen by 2.4% this quarter and gained 3.3% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 80% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Xeris Biopharma Holdings, Inc. is $10.00, about 18.9% above its last closing price of $8.11
This summary was machine generated from LSEG data August 6 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.00
-0.18
Missed
Mar. 31 2026 
-0.01
0.01
Beat
Dec. 31 2025 
0.04
0.06
Beat
Sep. 30 2025 
0.00
0.00
Met